{
  "zip": "/Users/Matt/Downloads/New Folder With Items 2.zip",
  "pdf_count_deduped": 74,
  "match_count": 74,
  "selected_count": 50,
  "will_apply_count": 50,
  "will_skip_existing_count": 0,
  "low_confidence_count": 19,
  "selected": [
    {
      "pdf_name": "ABILIFY MAINTENA 960_Unbranded_AE GU_ IT-NPR-2500045.pdf",
      "best_doc": "ABILIFY MAINTENA 960_Unbranded_AE GU_ IT-NPR-2500045",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.31313131313131315,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/ABILIFY MAINTENA 960_Unbranded_AE GU_ IT-NPR-2500045.pdf",
      "size": 396549
    },
    {
      "pdf_name": "AE 1 NEW affinità recettoriale, PANSS e Impulsività.pdf",
      "best_doc": "AE 1 NEW affinità recettoriale, PANSS e Impulsività",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.5529411764705883,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/AE 1 NEW affinità recettoriale, PANSS e Impulsività.pdf",
      "size": 1703752
    },
    {
      "pdf_name": "AE INAQOVI Informazioni cliniche.pdf",
      "best_doc": "AE INAQOVI Informazioni cliniche",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.4098360655737705,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/AE INAQOVI Informazioni cliniche.pdf",
      "size": 497779
    },
    {
      "pdf_name": "AE Masterclass.pdf",
      "best_doc": "AE Masterclass",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.3939393939393939,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/AE Masterclass.pdf",
      "size": 148979
    },
    {
      "pdf_name": "AM960 VAE DE - Einladung_Schlaglicht Psychiatrie_2026.pdf",
      "best_doc": "AM960 VAE DE - Einladung_Schlaglicht Psychiatrie_2026",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.04761904761904767,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/AM960 VAE DE - Einladung_Schlaglicht Psychiatrie_2026.pdf",
      "size": 2414811
    },
    {
      "pdf_name": "AT - HCP Einwilligung für Otsuka E-Mails Österreich.pdf",
      "best_doc": "AT - HCP Einwilligung für Otsuka E-Mails Österreich",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/AT - HCP Einwilligung für Otsuka E-Mails Österreich.pdf",
      "size": 365176
    },
    {
      "pdf_name": "AT - HCP Einwilligung für Remote Calls Österreich.pdf",
      "best_doc": "AT - HCP Einwilligung für Remote Calls Österreich",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/AT - HCP Einwilligung für Remote Calls Österreich.pdf",
      "size": 320848
    },
    {
      "pdf_name": "CH - HCP Einwilligung für Otsuka E-Mails Schweiz (de).pdf",
      "best_doc": "CH - HCP Einwilligung für Otsuka E-Mails Schweiz (de)",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/CH - HCP Einwilligung für Otsuka E-Mails Schweiz (de).pdf",
      "size": 408856
    },
    {
      "pdf_name": "CH - HCP Einwilligung für Remote Calls Schweiz (de).pdf",
      "best_doc": "CH - HCP Einwilligung für Remote Calls Schweiz (de)",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/CH - HCP Einwilligung für Remote Calls Schweiz (de).pdf",
      "size": 415528
    },
    {
      "pdf_name": "DACH (AT) HCP NPS Survey VAE 2025 (1).pdf",
      "best_doc": "DACH (AT) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.06451612903225812,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DACH (AT) HCP NPS Survey VAE 2025 (1).pdf",
      "size": 483659
    },
    {
      "pdf_name": "DACH (CH de) HCP NPS Survey VAE 2025 (1).pdf",
      "best_doc": "DACH (CH de) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.0461538461538461,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/DACH (CH de) HCP NPS Survey VAE 2025 (1).pdf",
      "size": 688754
    },
    {
      "pdf_name": "DACH (CH fr) HCP NPS Survey VAE 2025 (1).pdf",
      "best_doc": "DACH (CH fr) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.05882352941176472,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/DACH (CH fr) HCP NPS Survey VAE 2025 (1).pdf",
      "size": 450974
    },
    {
      "pdf_name": "DACH (DE) HCP NPS Survey VAE 2025.pdf",
      "best_doc": "DACH (DE) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.0461538461538461,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DACH (DE) HCP NPS Survey VAE 2025.pdf",
      "size": 428842
    },
    {
      "pdf_name": "DE - HCP Einwilligung für Otsuka E-Mails Deutschland.pdf",
      "best_doc": "DE - HCP Einwilligung für Otsuka E-Mails Deutschland",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.12244897959183676,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DE - HCP Einwilligung für Otsuka E-Mails Deutschland.pdf",
      "size": 556697
    },
    {
      "pdf_name": "DE - HCP Einwilligung für Remote Calls Deutschland.pdf",
      "best_doc": "DE - HCP Einwilligung für Remote Calls Deutschland",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.12244897959183676,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DE - HCP Einwilligung für Remote Calls Deutschland.pdf",
      "size": 564981
    },
    {
      "pdf_name": "Disclosure-Consent__Veeva-CRM__AT.pdf",
      "best_doc": "Disclosure-Consent__Veeva-CRM__AT",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.06451612903225812,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/Disclosure-Consent__Veeva-CRM__AT.pdf",
      "size": 157335
    },
    {
      "pdf_name": "Disclosure-Consent__Veeva-CRM__DE.pdf",
      "best_doc": "Disclosure-Consent__Veeva-CRM__DE",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.032258064516129004,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/Disclosure-Consent__Veeva-CRM__DE.pdf",
      "size": 157829
    },
    {
      "pdf_name": "INA VAE DE - Experteninterview Prof. Junghanß.pdf",
      "best_doc": "INA VAE DE - Experteninterview Prof. Junghanß",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.4444444444444444,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INA VAE DE - Experteninterview Prof. Junghanß.pdf",
      "size": 6254341
    },
    {
      "pdf_name": "INA VAE DE - Nachlese DGHO 2025 (Case).pdf",
      "best_doc": "INA VAE DE - Nachlese DGHO 2025 (Case)",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.23076923076923073,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INA VAE DE - Nachlese DGHO 2025 (Case).pdf",
      "size": 13412964
    },
    {
      "pdf_name": "INA VAE DE – EL DKK 2026 Berlin.pdf",
      "best_doc": "INA VAE DE – EL DKK 2026 Berlin",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.33333333333333337,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INA VAE DE – EL DKK 2026 Berlin.pdf",
      "size": 7911621
    },
    {
      "pdf_name": "OTSUKA_ABILIFY 960720_AE  -  IT-AM-2500012.pdf",
      "best_doc": "OTSUKA_ABILIFY 960/720_AE  -  IT-AM-2500012",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.2549019607843137,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/OTSUKA_ABILIFY 960720_AE  -  IT-AM-2500012.pdf",
      "size": 672901
    },
    {
      "pdf_name": "OTSUKA_ABILIFY 960720_Branded_AE lancio 960720_IT-AM2-2500122.pdf",
      "best_doc": "OTSUKA_ABILIFY 960/720_Branded_AE lancio 960/720_IT-AM2-2500122",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.2432432432432432,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/OTSUKA_ABILIFY 960720_Branded_AE lancio 960720_IT-AM2-2500122.pdf",
      "size": 3934193
    },
    {
      "pdf_name": "RXULTI_Branded_AE DE FILIPPIS_IT-RXU-2300072 (1).pdf",
      "best_doc": "RXULTI_Branded_AE DE FILIPPIS_IT-RXU-2300072",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.3191489361702128,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/RXULTI_Branded_AE DE FILIPPIS_IT-RXU-2300072 (1).pdf",
      "size": 2436966
    },
    {
      "pdf_name": "INAQOVI VAE DE - Infektionsrisiko (Entlastung Sorge bei AML-Patienten).pdf",
      "best_doc": "INA VAE DE - Infektionsrisiko (Entlastung Sorge bei AML-Patienten)",
      "score": 0.96875,
      "seq_ratio": 0.96875,
      "token_ratio": 0.8888888888888888,
      "margin": 0.5015967153284672,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - Infektionsrisiko (Entlastung Sorge bei AML-Patienten).pdf",
      "size": 6555637
    },
    {
      "pdf_name": "INA VAE AT - Sopro ÖÄZ 2025 Experteninterview Dr. Verena Petzer.pdf",
      "best_doc": "INA VAE AT EREP - Sopro ÖÄZ 2025 Experteninterview Dr. Verena Petzer",
      "score": 0.96,
      "seq_ratio": 0.96,
      "token_ratio": 0.9523809523809523,
      "margin": 0.3580582524271845,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INA VAE AT - Sopro ÖÄZ 2025 Experteninterview Dr. Verena Petzer.pdf",
      "size": 4746527
    },
    {
      "pdf_name": "DK AM2 E-mail Opstart uden oralt supplement Apr 25.pdf",
      "best_doc": "DK AM2 E-mail Opstart uden oralt supplement  Apr 25 DK-AM2-2500024",
      "score": 0.9523809523809523,
      "seq_ratio": 0.8695652173913043,
      "token_ratio": 0.9523809523809523,
      "margin": 0.3208020050125313,
      "source_path": "New Folder With Items 2/OPDK.zip/OPDK/DK AM2 E-mail Opstart uden oralt supplement Apr 25.pdf",
      "size": 288993
    },
    {
      "pdf_name": "VAE DE - Patientenmaterial SamMY und Angehörigenbroschüre.pdf",
      "best_doc": "AM960 VAE DE - Patientenmaterial SamMY und Angehörigenbroschüre",
      "score": 0.9482758620689655,
      "seq_ratio": 0.9482758620689655,
      "token_ratio": 0.9230769230769231,
      "margin": 0.4482758620689655,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/VAE DE - Patientenmaterial SamMY und Angehörigenbroschüre.pdf",
      "size": 182089
    },
    {
      "pdf_name": "INAQOVI VAE DE - EHA 2025 Otsuka Symposium (1).pdf",
      "best_doc": "INA VAE DE - EHA 2025 Otsuka Symposium",
      "score": 0.9473684210526315,
      "seq_ratio": 0.9473684210526315,
      "token_ratio": 0.8571428571428571,
      "margin": 0.3157894736842105,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - EHA 2025 Otsuka Symposium (1).pdf",
      "size": 1104963
    },
    {
      "pdf_name": "VAE AM960 Patientenwünsche Baune - Citrome_Update 04.2025.pdf",
      "best_doc": "AM960 VAE DE - Patientenwünsche Baune/Citrome_Update 04.2025",
      "score": 0.9411764705882353,
      "seq_ratio": 0.9026548672566371,
      "token_ratio": 0.9411764705882353,
      "margin": 0.27450980392156865,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/VAE AM960 Patientenwünsche Baune - Citrome_Update 04.2025.pdf",
      "size": 5373447
    },
    {
      "pdf_name": "A2M_VAE DE AM960 - Podcast_Köhler_1025.pdf",
      "best_doc": "VAE DE AM960 - Podcast_Köhler_1025",
      "score": 0.9411764705882353,
      "seq_ratio": 0.9411764705882353,
      "token_ratio": 0.9230769230769231,
      "margin": 0.35889798957557706,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_VAE DE AM960 - Podcast_Köhler_1025.pdf",
      "size": 3390624
    },
    {
      "pdf_name": "INAQOVI VAE DE - Einladung DGHO 2025 (1).pdf",
      "best_doc": "INA VAE DE - Einladung DGHO 2025",
      "score": 0.9375,
      "seq_ratio": 0.9375,
      "token_ratio": 0.8333333333333334,
      "margin": 0.24305555555555558,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - Einladung DGHO 2025 (1).pdf",
      "size": 4439590
    },
    {
      "pdf_name": "INAQOVI VAE AT - Kitteltaschenkarte 04.25.pdf",
      "best_doc": "INAQOVI VAE AT - E-REP_Kitteltaschenkarte 04.25",
      "score": 0.9285714285714286,
      "seq_ratio": 0.9285714285714286,
      "token_ratio": 0.8571428571428571,
      "margin": 0.23089700996677742,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - Kitteltaschenkarte 04.25.pdf",
      "size": 2092480
    },
    {
      "pdf_name": "INAQOVI DE VAE - Neues vom DGHO Orale Therapie für unfitte AML-Patienten.pdf",
      "best_doc": "INA VAE DE - Neues vom DGHO: Orale Therapie für unfitte AML-Patienten",
      "score": 0.9264705882352942,
      "seq_ratio": 0.9264705882352942,
      "token_ratio": 0.9166666666666666,
      "margin": 0.03914664457332229,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI DE VAE - Neues vom DGHO Orale Therapie für unfitte AML-Patienten.pdf",
      "size": 3785782
    },
    {
      "pdf_name": "A2M_VAE DE AM720 - Launch 04-25.pdf",
      "best_doc": "VAE DE AM720 - Launch 04/25",
      "score": 0.9259259259259259,
      "seq_ratio": 0.9259259259259259,
      "token_ratio": 0.9230769230769231,
      "margin": 0.37207977207977205,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_VAE DE AM720 - Launch 04-25.pdf",
      "size": 3471505
    },
    {
      "pdf_name": "A2M VAE_Studienübersicht_Update 04.2025.pdf",
      "best_doc": "AM960 VAE DE - Studienübersicht Update 04.2025",
      "score": 0.9156626506024096,
      "seq_ratio": 0.9156626506024096,
      "token_ratio": 0.7692307692307693,
      "margin": 0.2764873928704509,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M VAE_Studienübersicht_Update 04.2025.pdf",
      "size": 3091575
    },
    {
      "pdf_name": "VAE curso FH Fundamentos SCZ APA.pdf",
      "best_doc": "FH - Curso Fundamentos SCZ APA",
      "score": 0.9090909090909091,
      "seq_ratio": 0.8666666666666667,
      "token_ratio": 0.9090909090909091,
      "margin": 0.40909090909090906,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/VAE curso FH Fundamentos SCZ APA.pdf",
      "size": 286127
    },
    {
      "pdf_name": "INA - VAE Simposio SEHH 2025.pdf",
      "best_doc": "INA - VAE Videos Simposio SEHH 2025",
      "score": 0.9090909090909091,
      "seq_ratio": 0.8813559322033898,
      "token_ratio": 0.9090909090909091,
      "margin": 0.19480519480519476,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/INA - VAE Simposio SEHH 2025.pdf",
      "size": 325947
    },
    {
      "pdf_name": "VAE AT Jinarc Grüne Box.pdf",
      "best_doc": "VAE AT - Jinarc Grüne Box (Nephrologie)",
      "score": 0.9090909090909091,
      "seq_ratio": 0.7931034482758621,
      "token_ratio": 0.9090909090909091,
      "margin": 0.4178628389154705,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT Jinarc Grüne Box.pdf",
      "size": 309336
    },
    {
      "pdf_name": "VAE AT E-REP - SoftConsent.pdf",
      "best_doc": "VAE AT E-REP - SoftConsent (Rheumatologie)",
      "score": 0.9090909090909091,
      "seq_ratio": 0.7741935483870968,
      "token_ratio": 0.9090909090909091,
      "margin": 0.24242424242424243,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - SoftConsent.pdf",
      "size": 342772
    },
    {
      "pdf_name": "NORDICS HCP Survey Email - Belgium (ET-1682).pdf",
      "best_doc": "NORDICS HCP Survey Email - Belgium - June 2025",
      "score": 0.8780487804878049,
      "seq_ratio": 0.8780487804878049,
      "token_ratio": 0.7142857142857143,
      "margin": 0.1707317073170732,
      "source_path": "New Folder With Items 2/Emails (2).zip/Emails/NORDICS HCP Survey Email - Belgium (ET-1682).pdf",
      "size": 219070
    },
    {
      "pdf_name": "INAQOVI VAE AT - EL OeGHO 2026 Bregenz.pdf",
      "best_doc": "INA VAE AT EREP – EL OeGHO 2026 Bregenz",
      "score": 0.8767123287671232,
      "seq_ratio": 0.8767123287671232,
      "token_ratio": 0.8,
      "margin": 0.17791714804423164,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - EL OeGHO 2026 Bregenz.pdf",
      "size": 6764072
    },
    {
      "pdf_name": "VAE DE INAQOVI - Summed Up 09.25.pdf",
      "best_doc": "VAE DE Inaqovi - Einladung Summed Up 30.09.25",
      "score": 0.875,
      "seq_ratio": 0.821917808219178,
      "token_ratio": 0.875,
      "margin": 0.15705128205128205,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/VAE DE INAQOVI - Summed Up 09.25.pdf",
      "size": 903633
    },
    {
      "pdf_name": "A2M_VAE_Patientenvorteile_Switch 400-960_2025-07.pdf",
      "best_doc": "VAE DE AM960 - Patientenvorteile Switch 400 - 960_2025-07",
      "score": 0.8712871287128713,
      "seq_ratio": 0.8712871287128713,
      "token_ratio": 0.8235294117647058,
      "margin": 0.2998585572842999,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_VAE_Patientenvorteile_Switch 400-960_2025-07.pdf",
      "size": 3992801
    },
    {
      "pdf_name": "VAE CH-DE - Interview Prof. Peri LO.pdf",
      "best_doc": "VAE CH-DE - Interview Prof. Peri (Endokrinologie)",
      "score": 0.8571428571428571,
      "seq_ratio": 0.8421052631578947,
      "token_ratio": 0.8571428571428571,
      "margin": 0.2704761904761904,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/VAE CH-DE - Interview Prof. Peri LO.pdf",
      "size": 347523
    },
    {
      "pdf_name": "INAQOVI VAE DE - Ein- und Umstellung 04.25 (1).pdf",
      "best_doc": "INA VAE DE - Ein- und Umstellung",
      "score": 0.8529411764705882,
      "seq_ratio": 0.8529411764705882,
      "token_ratio": 0.7142857142857143,
      "margin": 0.20177838577291374,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - Ein- und Umstellung 04.25 (1).pdf",
      "size": 3497185
    },
    {
      "pdf_name": "INAQOVI VAE AT - OeGHO-Kongress 2025 Symposiumsbericht.pdf",
      "best_doc": "INAQOVI VAE AT EREP- OeGHO-Kongress 2025 Bericht",
      "score": 0.8484848484848485,
      "seq_ratio": 0.8484848484848485,
      "token_ratio": 0.8,
      "margin": 0.2770562770562771,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - OeGHO-Kongress 2025 Symposiumsbericht.pdf",
      "size": 1031248
    },
    {
      "pdf_name": "LUP - Poster Deep Response Promocional.pdf",
      "best_doc": "LUP - Poster Deep Response - reuma",
      "score": 0.8484848484848485,
      "seq_ratio": 0.8484848484848485,
      "token_ratio": 0.8,
      "margin": 0.030303030303030276,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/LUP - Poster Deep Response Promocional.pdf",
      "size": 4821370
    },
    {
      "pdf_name": "ES Approved Email Consent (ET-2722).pdf",
      "best_doc": "Approved Email Consent - 2",
      "score": 0.8421052631578947,
      "seq_ratio": 0.8421052631578947,
      "token_ratio": 0.6,
      "margin": 0.2152395915161036,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/ES Approved Email Consent (ET-2722).pdf",
      "size": 115656
    },
    {
      "pdf_name": "INQOVI VAE DE - NL EHA Versand.pdf",
      "best_doc": "INA VAE DE - EHA NL – Versand",
      "score": 0.8333333333333334,
      "seq_ratio": 0.8148148148148148,
      "token_ratio": 0.8333333333333334,
      "margin": 0.16666666666666674,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INQOVI VAE DE - NL EHA Versand.pdf",
      "size": 1159886
    },
    {
      "pdf_name": "Curso IA en Salud - VAE.pdf",
      "best_doc": "FH - Curso IA en Salud",
      "score": 0.8292682926829268,
      "seq_ratio": 0.8292682926829268,
      "token_ratio": 0.8,
      "margin": 0.2838137472283814,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/Curso IA en Salud - VAE.pdf",
      "size": 307892
    }
  ],
  "will_apply": [
    {
      "pdf_name": "ABILIFY MAINTENA 960_Unbranded_AE GU_ IT-NPR-2500045.pdf",
      "best_doc": "ABILIFY MAINTENA 960_Unbranded_AE GU_ IT-NPR-2500045",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.31313131313131315,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/ABILIFY MAINTENA 960_Unbranded_AE GU_ IT-NPR-2500045.pdf",
      "size": 396549
    },
    {
      "pdf_name": "AE 1 NEW affinità recettoriale, PANSS e Impulsività.pdf",
      "best_doc": "AE 1 NEW affinità recettoriale, PANSS e Impulsività",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.5529411764705883,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/AE 1 NEW affinità recettoriale, PANSS e Impulsività.pdf",
      "size": 1703752
    },
    {
      "pdf_name": "AE INAQOVI Informazioni cliniche.pdf",
      "best_doc": "AE INAQOVI Informazioni cliniche",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.4098360655737705,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/AE INAQOVI Informazioni cliniche.pdf",
      "size": 497779
    },
    {
      "pdf_name": "AE Masterclass.pdf",
      "best_doc": "AE Masterclass",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.3939393939393939,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/AE Masterclass.pdf",
      "size": 148979
    },
    {
      "pdf_name": "AM960 VAE DE - Einladung_Schlaglicht Psychiatrie_2026.pdf",
      "best_doc": "AM960 VAE DE - Einladung_Schlaglicht Psychiatrie_2026",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.04761904761904767,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/AM960 VAE DE - Einladung_Schlaglicht Psychiatrie_2026.pdf",
      "size": 2414811
    },
    {
      "pdf_name": "AT - HCP Einwilligung für Otsuka E-Mails Österreich.pdf",
      "best_doc": "AT - HCP Einwilligung für Otsuka E-Mails Österreich",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/AT - HCP Einwilligung für Otsuka E-Mails Österreich.pdf",
      "size": 365176
    },
    {
      "pdf_name": "AT - HCP Einwilligung für Remote Calls Österreich.pdf",
      "best_doc": "AT - HCP Einwilligung für Remote Calls Österreich",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/AT - HCP Einwilligung für Remote Calls Österreich.pdf",
      "size": 320848
    },
    {
      "pdf_name": "CH - HCP Einwilligung für Otsuka E-Mails Schweiz (de).pdf",
      "best_doc": "CH - HCP Einwilligung für Otsuka E-Mails Schweiz (de)",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/CH - HCP Einwilligung für Otsuka E-Mails Schweiz (de).pdf",
      "size": 408856
    },
    {
      "pdf_name": "CH - HCP Einwilligung für Remote Calls Schweiz (de).pdf",
      "best_doc": "CH - HCP Einwilligung für Remote Calls Schweiz (de)",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.125,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/CH - HCP Einwilligung für Remote Calls Schweiz (de).pdf",
      "size": 415528
    },
    {
      "pdf_name": "DACH (AT) HCP NPS Survey VAE 2025 (1).pdf",
      "best_doc": "DACH (AT) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.06451612903225812,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DACH (AT) HCP NPS Survey VAE 2025 (1).pdf",
      "size": 483659
    },
    {
      "pdf_name": "DACH (CH de) HCP NPS Survey VAE 2025 (1).pdf",
      "best_doc": "DACH (CH de) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.0461538461538461,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/DACH (CH de) HCP NPS Survey VAE 2025 (1).pdf",
      "size": 688754
    },
    {
      "pdf_name": "DACH (CH fr) HCP NPS Survey VAE 2025 (1).pdf",
      "best_doc": "DACH (CH fr) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.05882352941176472,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/DACH (CH fr) HCP NPS Survey VAE 2025 (1).pdf",
      "size": 450974
    },
    {
      "pdf_name": "DACH (DE) HCP NPS Survey VAE 2025.pdf",
      "best_doc": "DACH (DE) HCP NPS Survey VAE 2025",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.0461538461538461,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DACH (DE) HCP NPS Survey VAE 2025.pdf",
      "size": 428842
    },
    {
      "pdf_name": "DE - HCP Einwilligung für Otsuka E-Mails Deutschland.pdf",
      "best_doc": "DE - HCP Einwilligung für Otsuka E-Mails Deutschland",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.12244897959183676,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DE - HCP Einwilligung für Otsuka E-Mails Deutschland.pdf",
      "size": 556697
    },
    {
      "pdf_name": "DE - HCP Einwilligung für Remote Calls Deutschland.pdf",
      "best_doc": "DE - HCP Einwilligung für Remote Calls Deutschland",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.12244897959183676,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/DE - HCP Einwilligung für Remote Calls Deutschland.pdf",
      "size": 564981
    },
    {
      "pdf_name": "Disclosure-Consent__Veeva-CRM__AT.pdf",
      "best_doc": "Disclosure-Consent__Veeva-CRM__AT",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.06451612903225812,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/Disclosure-Consent__Veeva-CRM__AT.pdf",
      "size": 157335
    },
    {
      "pdf_name": "Disclosure-Consent__Veeva-CRM__DE.pdf",
      "best_doc": "Disclosure-Consent__Veeva-CRM__DE",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.032258064516129004,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/Disclosure-Consent__Veeva-CRM__DE.pdf",
      "size": 157829
    },
    {
      "pdf_name": "INA VAE DE - Experteninterview Prof. Junghanß.pdf",
      "best_doc": "INA VAE DE - Experteninterview Prof. Junghanß",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.4444444444444444,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INA VAE DE - Experteninterview Prof. Junghanß.pdf",
      "size": 6254341
    },
    {
      "pdf_name": "INA VAE DE - Nachlese DGHO 2025 (Case).pdf",
      "best_doc": "INA VAE DE - Nachlese DGHO 2025 (Case)",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.23076923076923073,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INA VAE DE - Nachlese DGHO 2025 (Case).pdf",
      "size": 13412964
    },
    {
      "pdf_name": "INA VAE DE – EL DKK 2026 Berlin.pdf",
      "best_doc": "INA VAE DE – EL DKK 2026 Berlin",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.33333333333333337,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INA VAE DE – EL DKK 2026 Berlin.pdf",
      "size": 7911621
    },
    {
      "pdf_name": "OTSUKA_ABILIFY 960720_AE  -  IT-AM-2500012.pdf",
      "best_doc": "OTSUKA_ABILIFY 960/720_AE  -  IT-AM-2500012",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.2549019607843137,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/OTSUKA_ABILIFY 960720_AE  -  IT-AM-2500012.pdf",
      "size": 672901
    },
    {
      "pdf_name": "OTSUKA_ABILIFY 960720_Branded_AE lancio 960720_IT-AM2-2500122.pdf",
      "best_doc": "OTSUKA_ABILIFY 960/720_Branded_AE lancio 960/720_IT-AM2-2500122",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.2432432432432432,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/OTSUKA_ABILIFY 960720_Branded_AE lancio 960720_IT-AM2-2500122.pdf",
      "size": 3934193
    },
    {
      "pdf_name": "RXULTI_Branded_AE DE FILIPPIS_IT-RXU-2300072 (1).pdf",
      "best_doc": "RXULTI_Branded_AE DE FILIPPIS_IT-RXU-2300072",
      "score": 1.0,
      "seq_ratio": 1.0,
      "token_ratio": 1.0,
      "margin": 0.3191489361702128,
      "source_path": "New Folder With Items 2/Emails (4).zip/Emails/RXULTI_Branded_AE DE FILIPPIS_IT-RXU-2300072 (1).pdf",
      "size": 2436966
    },
    {
      "pdf_name": "INAQOVI VAE DE - Infektionsrisiko (Entlastung Sorge bei AML-Patienten).pdf",
      "best_doc": "INA VAE DE - Infektionsrisiko (Entlastung Sorge bei AML-Patienten)",
      "score": 0.96875,
      "seq_ratio": 0.96875,
      "token_ratio": 0.8888888888888888,
      "margin": 0.5015967153284672,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - Infektionsrisiko (Entlastung Sorge bei AML-Patienten).pdf",
      "size": 6555637
    },
    {
      "pdf_name": "INA VAE AT - Sopro ÖÄZ 2025 Experteninterview Dr. Verena Petzer.pdf",
      "best_doc": "INA VAE AT EREP - Sopro ÖÄZ 2025 Experteninterview Dr. Verena Petzer",
      "score": 0.96,
      "seq_ratio": 0.96,
      "token_ratio": 0.9523809523809523,
      "margin": 0.3580582524271845,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INA VAE AT - Sopro ÖÄZ 2025 Experteninterview Dr. Verena Petzer.pdf",
      "size": 4746527
    },
    {
      "pdf_name": "DK AM2 E-mail Opstart uden oralt supplement Apr 25.pdf",
      "best_doc": "DK AM2 E-mail Opstart uden oralt supplement  Apr 25 DK-AM2-2500024",
      "score": 0.9523809523809523,
      "seq_ratio": 0.8695652173913043,
      "token_ratio": 0.9523809523809523,
      "margin": 0.3208020050125313,
      "source_path": "New Folder With Items 2/OPDK.zip/OPDK/DK AM2 E-mail Opstart uden oralt supplement Apr 25.pdf",
      "size": 288993
    },
    {
      "pdf_name": "VAE DE - Patientenmaterial SamMY und Angehörigenbroschüre.pdf",
      "best_doc": "AM960 VAE DE - Patientenmaterial SamMY und Angehörigenbroschüre",
      "score": 0.9482758620689655,
      "seq_ratio": 0.9482758620689655,
      "token_ratio": 0.9230769230769231,
      "margin": 0.4482758620689655,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/VAE DE - Patientenmaterial SamMY und Angehörigenbroschüre.pdf",
      "size": 182089
    },
    {
      "pdf_name": "INAQOVI VAE DE - EHA 2025 Otsuka Symposium (1).pdf",
      "best_doc": "INA VAE DE - EHA 2025 Otsuka Symposium",
      "score": 0.9473684210526315,
      "seq_ratio": 0.9473684210526315,
      "token_ratio": 0.8571428571428571,
      "margin": 0.3157894736842105,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - EHA 2025 Otsuka Symposium (1).pdf",
      "size": 1104963
    },
    {
      "pdf_name": "VAE AM960 Patientenwünsche Baune - Citrome_Update 04.2025.pdf",
      "best_doc": "AM960 VAE DE - Patientenwünsche Baune/Citrome_Update 04.2025",
      "score": 0.9411764705882353,
      "seq_ratio": 0.9026548672566371,
      "token_ratio": 0.9411764705882353,
      "margin": 0.27450980392156865,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/VAE AM960 Patientenwünsche Baune - Citrome_Update 04.2025.pdf",
      "size": 5373447
    },
    {
      "pdf_name": "A2M_VAE DE AM960 - Podcast_Köhler_1025.pdf",
      "best_doc": "VAE DE AM960 - Podcast_Köhler_1025",
      "score": 0.9411764705882353,
      "seq_ratio": 0.9411764705882353,
      "token_ratio": 0.9230769230769231,
      "margin": 0.35889798957557706,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_VAE DE AM960 - Podcast_Köhler_1025.pdf",
      "size": 3390624
    },
    {
      "pdf_name": "INAQOVI VAE DE - Einladung DGHO 2025 (1).pdf",
      "best_doc": "INA VAE DE - Einladung DGHO 2025",
      "score": 0.9375,
      "seq_ratio": 0.9375,
      "token_ratio": 0.8333333333333334,
      "margin": 0.24305555555555558,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - Einladung DGHO 2025 (1).pdf",
      "size": 4439590
    },
    {
      "pdf_name": "INAQOVI VAE AT - Kitteltaschenkarte 04.25.pdf",
      "best_doc": "INAQOVI VAE AT - E-REP_Kitteltaschenkarte 04.25",
      "score": 0.9285714285714286,
      "seq_ratio": 0.9285714285714286,
      "token_ratio": 0.8571428571428571,
      "margin": 0.23089700996677742,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - Kitteltaschenkarte 04.25.pdf",
      "size": 2092480
    },
    {
      "pdf_name": "INAQOVI DE VAE - Neues vom DGHO Orale Therapie für unfitte AML-Patienten.pdf",
      "best_doc": "INA VAE DE - Neues vom DGHO: Orale Therapie für unfitte AML-Patienten",
      "score": 0.9264705882352942,
      "seq_ratio": 0.9264705882352942,
      "token_ratio": 0.9166666666666666,
      "margin": 0.03914664457332229,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI DE VAE - Neues vom DGHO Orale Therapie für unfitte AML-Patienten.pdf",
      "size": 3785782
    },
    {
      "pdf_name": "A2M_VAE DE AM720 - Launch 04-25.pdf",
      "best_doc": "VAE DE AM720 - Launch 04/25",
      "score": 0.9259259259259259,
      "seq_ratio": 0.9259259259259259,
      "token_ratio": 0.9230769230769231,
      "margin": 0.37207977207977205,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_VAE DE AM720 - Launch 04-25.pdf",
      "size": 3471505
    },
    {
      "pdf_name": "A2M VAE_Studienübersicht_Update 04.2025.pdf",
      "best_doc": "AM960 VAE DE - Studienübersicht Update 04.2025",
      "score": 0.9156626506024096,
      "seq_ratio": 0.9156626506024096,
      "token_ratio": 0.7692307692307693,
      "margin": 0.2764873928704509,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M VAE_Studienübersicht_Update 04.2025.pdf",
      "size": 3091575
    },
    {
      "pdf_name": "VAE curso FH Fundamentos SCZ APA.pdf",
      "best_doc": "FH - Curso Fundamentos SCZ APA",
      "score": 0.9090909090909091,
      "seq_ratio": 0.8666666666666667,
      "token_ratio": 0.9090909090909091,
      "margin": 0.40909090909090906,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/VAE curso FH Fundamentos SCZ APA.pdf",
      "size": 286127
    },
    {
      "pdf_name": "INA - VAE Simposio SEHH 2025.pdf",
      "best_doc": "INA - VAE Videos Simposio SEHH 2025",
      "score": 0.9090909090909091,
      "seq_ratio": 0.8813559322033898,
      "token_ratio": 0.9090909090909091,
      "margin": 0.19480519480519476,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/INA - VAE Simposio SEHH 2025.pdf",
      "size": 325947
    },
    {
      "pdf_name": "VAE AT Jinarc Grüne Box.pdf",
      "best_doc": "VAE AT - Jinarc Grüne Box (Nephrologie)",
      "score": 0.9090909090909091,
      "seq_ratio": 0.7931034482758621,
      "token_ratio": 0.9090909090909091,
      "margin": 0.4178628389154705,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT Jinarc Grüne Box.pdf",
      "size": 309336
    },
    {
      "pdf_name": "VAE AT E-REP - SoftConsent.pdf",
      "best_doc": "VAE AT E-REP - SoftConsent (Rheumatologie)",
      "score": 0.9090909090909091,
      "seq_ratio": 0.7741935483870968,
      "token_ratio": 0.9090909090909091,
      "margin": 0.24242424242424243,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - SoftConsent.pdf",
      "size": 342772
    },
    {
      "pdf_name": "NORDICS HCP Survey Email - Belgium (ET-1682).pdf",
      "best_doc": "NORDICS HCP Survey Email - Belgium - June 2025",
      "score": 0.8780487804878049,
      "seq_ratio": 0.8780487804878049,
      "token_ratio": 0.7142857142857143,
      "margin": 0.1707317073170732,
      "source_path": "New Folder With Items 2/Emails (2).zip/Emails/NORDICS HCP Survey Email - Belgium (ET-1682).pdf",
      "size": 219070
    },
    {
      "pdf_name": "INAQOVI VAE AT - EL OeGHO 2026 Bregenz.pdf",
      "best_doc": "INA VAE AT EREP – EL OeGHO 2026 Bregenz",
      "score": 0.8767123287671232,
      "seq_ratio": 0.8767123287671232,
      "token_ratio": 0.8,
      "margin": 0.17791714804423164,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - EL OeGHO 2026 Bregenz.pdf",
      "size": 6764072
    },
    {
      "pdf_name": "VAE DE INAQOVI - Summed Up 09.25.pdf",
      "best_doc": "VAE DE Inaqovi - Einladung Summed Up 30.09.25",
      "score": 0.875,
      "seq_ratio": 0.821917808219178,
      "token_ratio": 0.875,
      "margin": 0.15705128205128205,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/VAE DE INAQOVI - Summed Up 09.25.pdf",
      "size": 903633
    },
    {
      "pdf_name": "A2M_VAE_Patientenvorteile_Switch 400-960_2025-07.pdf",
      "best_doc": "VAE DE AM960 - Patientenvorteile Switch 400 - 960_2025-07",
      "score": 0.8712871287128713,
      "seq_ratio": 0.8712871287128713,
      "token_ratio": 0.8235294117647058,
      "margin": 0.2998585572842999,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_VAE_Patientenvorteile_Switch 400-960_2025-07.pdf",
      "size": 3992801
    },
    {
      "pdf_name": "VAE CH-DE - Interview Prof. Peri LO.pdf",
      "best_doc": "VAE CH-DE - Interview Prof. Peri (Endokrinologie)",
      "score": 0.8571428571428571,
      "seq_ratio": 0.8421052631578947,
      "token_ratio": 0.8571428571428571,
      "margin": 0.2704761904761904,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/VAE CH-DE - Interview Prof. Peri LO.pdf",
      "size": 347523
    },
    {
      "pdf_name": "INAQOVI VAE DE - Ein- und Umstellung 04.25 (1).pdf",
      "best_doc": "INA VAE DE - Ein- und Umstellung",
      "score": 0.8529411764705882,
      "seq_ratio": 0.8529411764705882,
      "token_ratio": 0.7142857142857143,
      "margin": 0.20177838577291374,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI VAE DE - Ein- und Umstellung 04.25 (1).pdf",
      "size": 3497185
    },
    {
      "pdf_name": "INAQOVI VAE AT - OeGHO-Kongress 2025 Symposiumsbericht.pdf",
      "best_doc": "INAQOVI VAE AT EREP- OeGHO-Kongress 2025 Bericht",
      "score": 0.8484848484848485,
      "seq_ratio": 0.8484848484848485,
      "token_ratio": 0.8,
      "margin": 0.2770562770562771,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - OeGHO-Kongress 2025 Symposiumsbericht.pdf",
      "size": 1031248
    },
    {
      "pdf_name": "LUP - Poster Deep Response Promocional.pdf",
      "best_doc": "LUP - Poster Deep Response - reuma",
      "score": 0.8484848484848485,
      "seq_ratio": 0.8484848484848485,
      "token_ratio": 0.8,
      "margin": 0.030303030303030276,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/LUP - Poster Deep Response Promocional.pdf",
      "size": 4821370
    },
    {
      "pdf_name": "ES Approved Email Consent (ET-2722).pdf",
      "best_doc": "Approved Email Consent - 2",
      "score": 0.8421052631578947,
      "seq_ratio": 0.8421052631578947,
      "token_ratio": 0.6,
      "margin": 0.2152395915161036,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/ES Approved Email Consent (ET-2722).pdf",
      "size": 115656
    },
    {
      "pdf_name": "INQOVI VAE DE - NL EHA Versand.pdf",
      "best_doc": "INA VAE DE - EHA NL – Versand",
      "score": 0.8333333333333334,
      "seq_ratio": 0.8148148148148148,
      "token_ratio": 0.8333333333333334,
      "margin": 0.16666666666666674,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INQOVI VAE DE - NL EHA Versand.pdf",
      "size": 1159886
    },
    {
      "pdf_name": "Curso IA en Salud - VAE.pdf",
      "best_doc": "FH - Curso IA en Salud",
      "score": 0.8292682926829268,
      "seq_ratio": 0.8292682926829268,
      "token_ratio": 0.8,
      "margin": 0.2838137472283814,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/Curso IA en Salud - VAE.pdf",
      "size": 307892
    }
  ],
  "will_skip_existing": [],
  "low_confidence": [
    {
      "pdf_name": "VAE AT - Save the Date LN Webinar Nov 2025 OPEL.pdf",
      "best_doc": "VAE AT - Save the Date LN Webinar OPEL Nov 2025 (Infektiologie)",
      "score": 0.9523809523809523,
      "seq_ratio": 0.8269230769230769,
      "token_ratio": 0.9523809523809523,
      "margin": 0.0,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT - Save the Date LN Webinar Nov 2025 OPEL.pdf",
      "size": 756603
    },
    {
      "pdf_name": "VAE AT E-REP - Symposiumsbericht ÖGN Wintermeeting 2025.pdf",
      "best_doc": "VAE AT E-REP - Symposiumsbericht ÖGN Wintermeeting 2025 (Nephrologie)",
      "score": 0.9411764705882353,
      "seq_ratio": 0.8983050847457628,
      "token_ratio": 0.9411764705882353,
      "margin": 0.0,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - Symposiumsbericht ÖGN Wintermeeting 2025.pdf",
      "size": 309476
    },
    {
      "pdf_name": "VAE AT - Symposiumsbericht ÖGN Wintermeeting 2025.pdf",
      "best_doc": "VAE AT - Symposiumsbericht ÖGN Wintermeeting 2025 (Infektiologie)",
      "score": 0.9230769230769231,
      "seq_ratio": 0.8703703703703703,
      "token_ratio": 0.9230769230769231,
      "margin": 0.0,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT - Symposiumsbericht ÖGN Wintermeeting 2025.pdf",
      "size": 326328
    },
    {
      "pdf_name": "VAE AT INAQOVI - Summed Up 09.25.pdf",
      "best_doc": "VAE AT Inaqovi EREP - Einladung Summed Up 30.09.25",
      "score": 0.8235294117647058,
      "seq_ratio": 0.7692307692307693,
      "token_ratio": 0.8235294117647058,
      "margin": 0.0,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT INAQOVI - Summed Up 09.25.pdf",
      "size": 807835
    },
    {
      "pdf_name": "VAE AT E-REP - Einladung Lupologen Workshop NÖ-B-W 2026.pdf",
      "best_doc": "VAE AT E-REP - Einladung Lupologen WS NÖ/B/W (Rheumatologie)",
      "score": 0.8181818181818182,
      "seq_ratio": 0.7889908256880734,
      "token_ratio": 0.8181818181818182,
      "margin": 0.08550855085508557,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - Einladung Lupologen Workshop NÖ-B-W 2026.pdf",
      "size": 631903
    },
    {
      "pdf_name": "Spain HCP Survey Email 2025 (ET-2590).pdf",
      "best_doc": "Spain - HCP Survey Email - June 2025",
      "score": 0.8059701492537313,
      "seq_ratio": 0.8059701492537313,
      "token_ratio": 0.7692307692307693,
      "margin": 0.10008779631255482,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/Spain HCP Survey Email 2025 (ET-2590).pdf",
      "size": 141745
    },
    {
      "pdf_name": "VAE AT E-REP - CNI Differenzierung.pdf",
      "best_doc": "VAE AT E-REP - CNI Differenzierung V2.0 (Nephrologie)",
      "score": 0.8,
      "seq_ratio": 0.7901234567901234,
      "token_ratio": 0.8,
      "margin": 0.0,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - CNI Differenzierung.pdf",
      "size": 308788
    },
    {
      "pdf_name": "VAE AT E-REP - Save the Date Lupologen Workshop 2026.pdf",
      "best_doc": "VAE AT E-REP - Save the Date Lupologen WS (Nephrologie)",
      "score": 0.8,
      "seq_ratio": 0.7920792079207921,
      "token_ratio": 0.8,
      "margin": 0.0,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - Save the Date Lupologen Workshop 2026.pdf",
      "size": 487242
    },
    {
      "pdf_name": "INAQOVI VAE AT - Launch Kommunikation - Jetzt verfügbar 04.25.pdf",
      "best_doc": "INAQOVI VAE AT - E-REP_Launch Kommunikation 04.25",
      "score": 0.7884615384615384,
      "seq_ratio": 0.7884615384615384,
      "token_ratio": 0.7777777777777778,
      "margin": 0.20022624434389136,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INAQOVI VAE AT - Launch Kommunikation - Jetzt verfügbar 04.25.pdf",
      "size": 1706853
    },
    {
      "pdf_name": "VAE AT - Anmeldung LN Webinar Nov 2025 OPEL.pdf",
      "best_doc": "VAE AT - Einladung LN Webinar Nov 2025 (Nephrologie)",
      "score": 0.7865168539325843,
      "seq_ratio": 0.7865168539325843,
      "token_ratio": 0.75,
      "margin": 0.01728608470181503,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/VAE AT - Anmeldung LN Webinar Nov 2025 OPEL.pdf",
      "size": 479417
    },
    {
      "pdf_name": "INQOVI VAE AT - NL EHA Versand.pdf",
      "best_doc": "INA VAE AT GRIMALDI - EHA NL – Versand",
      "score": 0.7692307692307693,
      "seq_ratio": 0.7619047619047619,
      "token_ratio": 0.7692307692307693,
      "margin": 0.028490028490028574,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/INQOVI VAE AT - NL EHA Versand.pdf",
      "size": 1214046
    },
    {
      "pdf_name": "VAE AT - Save the Date Lupologen Workshop 2026.pdf",
      "best_doc": "VAE AT - Save the Date Lupologen WS (Nephrologie)",
      "score": 0.7640449438202247,
      "seq_ratio": 0.7640449438202247,
      "token_ratio": 0.75,
      "margin": 0.014044943820224698,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT - Save the Date Lupologen Workshop 2026.pdf",
      "size": 495724
    },
    {
      "pdf_name": "VAE AT E-REP - Symposium Report EULAR 2024.pdf",
      "best_doc": "VAE AT E-REP - Symposiumsbericht EULAR 2024 (Nephrologie)",
      "score": 0.7526881720430108,
      "seq_ratio": 0.7526881720430108,
      "token_ratio": 0.75,
      "margin": 0.0026881720430107503,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT E-REP - Symposium Report EULAR 2024.pdf",
      "size": 668314
    },
    {
      "pdf_name": "VAE AT - 3g UPCR.pdf",
      "best_doc": "VAE AT E-REP - 3g UPCR (Nephrologie)",
      "score": 0.7272727272727273,
      "seq_ratio": 0.6086956521739131,
      "token_ratio": 0.7272727272727273,
      "margin": 0.19393939393939397,
      "source_path": "New Folder With Items 2/Emails.zip/Emails/VAE AT - 3g UPCR.pdf",
      "size": 244630
    },
    {
      "pdf_name": "CLM Caso clínico con decitabina oral - Neutropenia en varón de 75 años (Dra. Gil).pdf",
      "best_doc": "INA - CC Neutropenia en varón de 75 años Dra. Gil",
      "score": 0.7213114754098361,
      "seq_ratio": 0.7213114754098361,
      "token_ratio": 0.6666666666666666,
      "margin": 0.22544370681479475,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/CLM Caso clínico con decitabina oral - Neutropenia en varón de 75 años (Dra. Gil).pdf",
      "size": 938500
    },
    {
      "pdf_name": "CLM Caso clínico con decitabina oral - Paciente vulnerable con LMA y mutacion TP53 (Dra. Tormo).pdf",
      "best_doc": "INA - CC Paciente vulnerable con LMA TP53 Dra. Tormo",
      "score": 0.6762589928057554,
      "seq_ratio": 0.6762589928057554,
      "token_ratio": 0.6086956521739131,
      "margin": 0.26749986871816417,
      "source_path": "New Folder With Items 2/Emails (5).zip/Emails/CLM Caso clínico con decitabina oral - Paciente vulnerable con LMA y mutacion TP53 (Dra. Tormo).pdf",
      "size": 914344
    },
    {
      "pdf_name": "A2M_Mailing_Print_Switch Oral 960_2025-09.pdf",
      "best_doc": "VAE DE AM960 - Switch Oral - 960_2025-09",
      "score": 0.6753246753246753,
      "seq_ratio": 0.6753246753246753,
      "token_ratio": 0.625,
      "margin": 0.14340978170765406,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/A2M_Mailing_Print_Switch Oral 960_2025-09.pdf",
      "size": 695778
    },
    {
      "pdf_name": "INAQOVI DE -Mailing-Anschreiben für FOMF-Webinar 09.25.pdf",
      "best_doc": "INAQOVI VAE DE - FOMF Webinar 30.09.2025",
      "score": 0.6373626373626373,
      "seq_ratio": 0.6373626373626373,
      "token_ratio": 0.5882352941176471,
      "margin": 0.09388437649307213,
      "source_path": "New Folder With Items 2/DACH.zip/DACH/Emails/INAQOVI DE -Mailing-Anschreiben für FOMF-Webinar 09.25.pdf",
      "size": 209881
    },
    {
      "pdf_name": "OPCH_A2M_VAE_Launchmailing_Brücken bauen_2025_DE.pdf",
      "best_doc": "ALL_Launch_960mg_2025_AM_de",
      "score": 0.48,
      "seq_ratio": 0.48,
      "token_ratio": 0.2857142857142857,
      "margin": 0.016585365853658496,
      "source_path": "New Folder With Items 2/Emails (3).zip/Emails/OPCH_A2M_VAE_Launchmailing_Brücken bauen_2025_DE.pdf",
      "size": 2128448
    }
  ]
}